Sanjivani Paranteral Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Sanjivani Paranteral Ltd is ₹ 147.4 as of 12 Jun 15:30 . The P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 35.2 on March 2025 . This represents a CAGR of 11.33% over 2 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 284.8 crore on March 2025 . This represents a CAGR of 27.45% over 2 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 13.81 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -38.24% The revenue of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 149.97 crore as compare to the Dec '25 revenue of ₹ 120.64 crore. This represent the growth of 24.31% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 2.17 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -47.46% The ebitda of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 36.56 crore as compare to the Dec '25 ebitda of ₹ 26.71 crore. This represent the growth of 36.88% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0.55 crore over 8 quarters. This represents a CAGR of -43.29% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 25.17 crore over 8 quarters. This represents a CAGR of 81.63% The Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Sanjivani Paranteral Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Sanjivani Paranteral Ltd or Syncom Formulations (India) Ltd?

Market cap of Sanjivani Paranteral Ltd is 181 Cr while Market cap of Syncom Formulations (India) Ltd is 1,343 Cr

What are the key factors driving the stock performance of Sanjivani Paranteral Ltd and Syncom Formulations (India) Ltd?

The stock performance of Sanjivani Paranteral Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanjivani Paranteral Ltd and Syncom Formulations (India) Ltd?

As of June 15, 2026, the Sanjivani Paranteral Ltd stock price is INR ₹147.4. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.29.

How do dividend payouts of Sanjivani Paranteral Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Sanjivani Paranteral Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.